Arcturus Therapeutics (ARCT) Tops Q3 EPS by 48c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($1.33), $0.48 better than the analyst estimate of ($1.81). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $3.42 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• RBC Capital Reiterates Sector Perform Rating on ExxonMobil (XOM)
• Microchip Technology completes acquisition of Hailo